Non-invasive sensor technology to be tested in a world-first sleep disorder trial

A world-first sleep disorder diagnosis and monitoring trial will be conducted using invisible sensor technology developed at RMIT University.

The trial is part of a new partnership between Australian research and technology company Sleeptite, RMIT and Flinders University.

Researchers will test Sleeptite's non-invasive sensor monitoring technology, REMi, and investigate its capability as a validation tool for sleep disorders.

REMi is the result of an industry-university collaboration that saw fundamental research taken from RMIT labs and translated into a commercial outcome.

Launched in March, the technology is designed to non-intrusively monitor aged care residents.

Sensors on the surface of a mattress provide real-time insights into residents' position, posture and sleep health status.

The technology will be put to the test by experts from the Flinders Health and Medical Research Institute Sleep Health team at Flinders University in collaboration with the Functional Materials and Microsystems Research Group at RMIT.

Group co-leader, Professor Madhu Bhaskaran, said the team was excited to take their collaboration with Sleeptite into important new areas of research.

The flexible and stretchable sensors developed at RMIT are part of what makes REMi unique - and it's this nearable and unfeelable technology that will enable sleep studies to be carried out in far more natural settings.

We look forward to discovering new avenues of partnership for this platform technology, and the opportunity to build deep collaborations to take this world-first system beyond aged care."

Professor Madhu Bhaskaran, Group Co-Leader

Sleeptite CEO Cameron van den Dungen said the new research harnessed REMi's potential to provide sleep diagnostic information outside of an aged care setting.

"I am so excited to see further scientific research show how the Sleeptite REMi platform can be used as a sleep diagnostic tool to determine sleep disorders such as sleep apnea," van den Dungen said.

Conducted at Flinders University's Adelaide research centre, the REMi Sleep Diagnosis Evaluation Trial is expected to last six months and will include:

• further sensor capability testing of the REMi sensors;
• identifying key sleep-related parameters;
• establishing relationships between sensor signals and sleep measurements; and,
• developing an algorithm that will recognize sleep quality.

The trial will involve 30 participants and will be evaluated against polysomnography (PSG) results, which are considered the industry gold standard.

Flinders University Project Lead, Associate Professor Andrew Vakulin, said the research aimed to develop and validate sleep measurement metrics and algorithms using the REMi sensors, and to further enhance their capability to provide informative data.

"Sleep, exercise and healthy eating are essential for a healthy life, and missing out on sleep - including with an untreated sleep disorder - can have serious long and short-term health consequences," Vakulin said.

"Our research aims to prove that the Sleeptite REMi sensors give a reliable measure of sleep quality and sleep disorders, which will ultimately lead to new apps to help consumers improve their sleep health."

The trial was made possible due to funding received from the CRC for Alertness, Safety and Productivity.